International multicenter, multiplatform study to validate Taipan snake venom time as a lupus anticoagulant screening test with ecarin time as the confirmatory test: Communication from the ISTH SSC Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. (10th October 2021)

• Record Type: Journal Article
• Authors: Moore, Gary W.; Jones, Paul O.; Platton, Sean; Hussain, Nadia; White, Danielle; Thomas, Will; Rigano, Joseph; Pouplard, Claire; Gray, Elaine; Devreese, Katrien M. J.
• Is Part Of: Journal of thrombosis and haemostasis. Volume 19:Number 12(2021)
• Page Start: 3177
• Page End: 3192
• Publication Date: 2021-10-10
• Subjects: Antiphospholipid syndrome -- Dilute Russell's viper venom time -- ecarin time -- lupus anticoagulant -- Taipan snake venom time -- validation; Thrombosis -- Periodicals; Hemostasis -- Periodicals; Blood coagulation disorders -- Periodicals; 616.1
• DOI: 10.1111/jth.15438
• Languages: English
• ISSNs: 1538-7933

Abstract

Abstract: Background: Lupus anticoagulant (LA) assays are compromised in anticoagulated patients, and existing strategies to overcome the interferences have limitations. The prothrombin‐activating Taipan snake venom time (TSVT) screening test and ecarin time (ET) confirmatory test are innately insensitive to vitamin K antagonists (VKA) and direct factor Xa inhibitors (DFXaI). Objectives: Validate standardized TSVT/ET reagents for LA detection, in a multicenter, multiplatform study. Patients/Methods: Six centers from four countries analyzed samples with TSVT/ET from 81 nonanticoagulated patients with LA, patients with established antiphospholipid syndrome (APS), and proven persistent LA who were either not anticoagulated ( n = 120) or were anticoagulated with VKAs ( n = 180) or DFXaIs ( n = 71). Additionally, 339 nonanticoagulated LA‐negative patients, and 575 anticoagulated non‐APS patients (172 VKA, 403 DFXaI) were tested. Anticoagulant spiking experiments were performed and 112 samples containing potential interferences (i.e., direct thrombin inhibitors) were tested. Results were evaluated against locally derived cutoffs. Imprecision was evaluated. Results: Cutoffs were remarkably similar despite use of different analyzers and donor populations. Cutoffs for TSVT ratio, ET ratio, percent correction, and normalized TSVT ratio/ET ratio ranged between 1.08 and 1.10, 1.09 and 1.12, 9.3% and 14.8%, and 1.10 and 1.15, respectively. Coefficients of variation for TSVT and ET ratios were ≤5.0%. TSVT/ET exhibited sensitivity, specificity, and negative and positive predictive values of 78.2%/95.0%/86.3%/91.5%, respectively, with established APS as the LA‐positive population, and 86.9%/95.0%/76.8%/97.4%, respectively, with triple‐positive APS. Interference was seen with direct thrombin inhibitors, unfractionated heparin, and low molecular weight heparins, but not VKAs or DFXaIs. Conclusions: TSVT/ET are validated for LA detection in nonanticoagulated patients and those on VKAs or DFXaIs.